Lumito

Bifogade filer

Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026

Kurs

0,00%

Likviditet

0,01 MSEK

Prenumeration

Kalender

	Est. tid*
2026-10-29	08:30	Kvartalsrapport 2026-Q3
2026-08-20	08:30	Kvartalsrapport 2026-Q2
2026-05-07	N/A	Årsstämma
2026-05-07	08:30	Kvartalsrapport 2026-Q1
2026-02-20	08:30	Bokslutskommuniké 2025
2026-02-06	-	Split LUMITO 500:1
2026-01-20	-	Extra Bolagsstämma 2026
2025-11-27	-	Kvartalsrapport 2025-Q3
2025-10-10	-	Extra Bolagsstämma 2025
2025-08-11	-	Kvartalsrapport 2025-Q2
2025-05-08	-	X-dag ordinarie utdelning LUMITO 0.00 SEK
2025-05-07	-	Årsstämma
2025-05-07	-	Kvartalsrapport 2025-Q1
2025-02-20	-	Bokslutskommuniké 2024
2024-10-31	-	Kvartalsrapport 2024-Q3
2024-08-23	-	Kvartalsrapport 2024-Q2
2024-05-08	-	X-dag ordinarie utdelning LUMITO 0.00 SEK
2024-05-07	-	Årsstämma
2024-05-07	-	Kvartalsrapport 2024-Q1
2024-02-22	-	Bokslutskommuniké 2023
2023-10-31	-	Kvartalsrapport 2023-Q3
2023-08-17	-	Kvartalsrapport 2023-Q2
2023-05-26	-	X-dag ordinarie utdelning LUMITO 0.00 SEK
2023-05-25	-	Årsstämma
2023-05-03	-	Kvartalsrapport 2023-Q1
2023-02-23	-	Bokslutskommuniké 2022
2022-11-02	-	Kvartalsrapport 2022-Q3
2022-08-18	-	Kvartalsrapport 2022-Q2
2022-05-30	-	X-dag ordinarie utdelning LUMITO 0.00 SEK
2022-05-27	-	Årsstämma
2022-05-06	-	Kvartalsrapport 2022-Q1
2022-02-17	-	Bokslutskommuniké 2021
2021-11-24	-	Extra Bolagsstämma 2021
2021-10-20	-	Kvartalsrapport 2021-Q3
2021-08-18	-	Kvartalsrapport 2021-Q2
2021-05-28	-	X-dag ordinarie utdelning LUMITO 0.00 SEK
2021-05-27	-	Årsstämma
2021-04-28	-	Kvartalsrapport 2021-Q1
2021-02-17	-	Bokslutskommuniké 2020
2020-11-03	-	Kvartalsrapport 2020-Q3
2020-08-20	-	Kvartalsrapport 2020-Q2
2020-05-28	-	X-dag ordinarie utdelning LUMITO 0.00 SEK
2020-05-27	-	Årsstämma
2020-04-28	-	Kvartalsrapport 2020-Q1
2020-02-17	-	Bokslutskommuniké 2019
2019-10-31	-	Kvartalsrapport 2019-Q3
2019-08-21	-	Kvartalsrapport 2019-Q2
2019-06-04	-	Årsstämma
2019-05-23	-	X-dag ordinarie utdelning LUMITO 0.00 SEK
2019-04-30	-	Kvartalsrapport 2019-Q1
2019-02-15	-	Bokslutskommuniké 2018

Beskrivning

Land	Sverige
Lista	Nordic SME Sweden
Sektor	Hälsovård
Industri	Medicinteknik

Lumito är ett svenskt bolag som utvecklar och marknadsför system för vävnads- och biomarköranalys inom digital patologi, byggda på uppkonverterande nanopartikelteknik. Bolaget riktar sig till vårdinrättningar, forskning och läkemedelssektorn. Bolaget bildades 2010 som en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026

2026-01-20 16:30:00

Lumito AB (publ) (“Lumito” or the “Company”) today announces that the composition of the Nomination Committee ahead of the Annual General Meeting 2026 has changed as a result of changes in the Company’s ownership structure.

The composition of the Nomination Committee ahead of the Annual General Meeting 2026, based on ownership statistics from Euroclear Sweden AB as of the last banking day of September 2025, was announced by press release on 5 December 2025. As a result of subsequent changes in ownership, the composition of the Nomination Committee has changed, with Jan Östlund (representing his own shareholding) stepping down from the Nomination Committee and Mikael Gustavsson (representing Tuvedalen Limited) joining as a new member of the Nomination Committee.

Following this change, the Nomination Committee ahead of the Annual General Meeting 2026 consists of the following members:

Mattias Pettersson, representing his own shareholding
Martin Wulf, representing DMC Byggnadsaktiebolag and Kent Danneteg
Mikael Gustavsson, representing Tuvedalen Limited

The Annual General Meeting of Lumito will be held on 7 May 2026 at Lumito’s offices, Scheelevägen 19, Lund.

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Lumito

Bifogade filer

Kurs 0,00%

Likviditet 0,01 MSEK